Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Enterobacteriaceae- related urinary tract infections

Ayhanim Tumturk; Senol Tonyali; Ayse Yasemin Tezer Tekce; Levent Isikay; Hakan Cime

doi:10.3855/jidc.10658

Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Enterobacteriaceae- related urinary tract infections

Authors

Ayhanim Tumturk University of Health Sciences, Clinic of Infectious Diseases, Turkiye Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey
Senol Tonyali University of Health Sciences, Clinic of Urology, Turkiye Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey
Ayse Yasemin Tezer Tekce University of Health Sciences, Clinic of Infectious Diseases, Turkiye Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey
Levent Isikay University of Health Sciences, Clinic of Urology, Turkiye Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey
Hakan Cime University of Health Sciences, Turkiye Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey

DOI:

https://doi.org/10.3855/jidc.10658

Keywords:

urinary tract infection, fosfomycin, enterobacteriaceae, Escherichia coli, klebsiellla

Abstract

Introduction: We aimed to demonstrate if fosfomycin tromethamine (FT) treatment could be the treatment of choice in ESBL-producing Enterobacteriaceae strains as an alternative to carbapenem particularly in patients who we would like to treat on an outpatient basis.

Methodology; We retrospectively analyzed the medical records of all patients who admitted to infectious disease outpatient clinic with complaints of dysuria and frequency and received FT for lower UTI between May 2016 and May 2017.

Results: A total of 48 patients, 19 females (39.6%) and 29 males (60.4%), with a mean age of 62.5 (ranging from 27 to 85) years were included the study. 26 (76.4%) of patients with a history of urinary operation or intervention had also a history of antibiotic use within the past 3 months. The isolated pathogens included Escherichia Coli (n = 32), Klebsiella spp. (n = 12), Enterobacter spp. (n = 4). The overall microbiological response after treatment was 70.8% (34/48) and the clinical response was 75% (36/48). Clinical and microbiological response rates of patients with and without urinary operation/intervention, diabetes mellitus, history of antibiotic use and malignancy were found similar (p > 0.05). However, patients with a urinary stone disease history had significantly higher response rates than those without a urinary stone disease history (P = 0.042).

Conclusion: Oral fosfomycin tromethamine might be the treatment of choice in ESBL-producing enterobactericea related UTIs especially caused by Escherichia Coli.

Downloads

Published

2019-01-31

How to Cite

Tumturk A, Tonyali S, Tezer Tekce AY, Isikay L, Cime H (2019) Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Enterobacteriaceae- related urinary tract infections. J Infect Dev Ctries 13:73–76. doi: 10.3855/jidc.10658

Download Citation

Endnote/Zotero/Mendeley (RIS)

Issue

Vol. 13 No. 01: January 2019

Section

Brief Original Articles

License

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).